2023
HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience
Podany P, Golastani R, Zhan H, Liang Y, Harigopal M, Krishnamurti U. HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience. American Journal Of Clinical Pathology 2023, 160: s9-s10. DOI: 10.1093/ajcp/aqad150.021.Peer-Reviewed Original ResearchLow HER2 expressionInvasive breast carcinomaIHC scoreHER2 expressionGroup 1Group 3HER2 immunohistochemistryHER2 testingGroup 2HER2 FISHGroup 4ASCO/CAP guidelinesGroup 5Single institutional experienceRecent clinical trialsStandard of careASCO/CAP 2018 guidelinesHER2/CEP17 ratioEquivocal HER2HER2 positivityTrastuzumab deruxtecanMore patientsCAP guidelinesPatient eligibilityCase report
2022
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncology 2022, 8: 1-4. PMID: 35113160, PMCID: PMC8814969, DOI: 10.1001/jamaoncol.2021.7239.Peer-Reviewed Original ResearchConceptsBreast cancer biopsiesT-DXdCancer biopsiesLarge randomized clinical trialsRandomized clinical trialsERBB2 protein expressionCentral pathology laboratoryBreast cancer tissuesAmerican Pathologists surveysStudy of concordanceTrastuzumab deruxtecanERBB2 positivityPatient populationClinical trialsScore 0Breast cancerImmunohistochemistry scoreCancer tissuesIHC assaysPatientsPathology laboratoryProtein expressionBiopsyIHCConcordance